Selecta Biosciences Company Profile (NASDAQ:SELB)

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Selecta Biosciences, Inc. (NASDAQ:SELB) posted its quarterly earnings data on Thursday, May, 11th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.40. The company earned $0.14 million during the quarter. Selecta Biosciences had a negative return on equity of 76.21% and a negative net margin of 715.40%. View Selecta Biosciences' Earnings History.

3 brokerages have issued 1-year price objectives for Selecta Biosciences' stock. Their predictions range from $25.00 to $32.00. On average, they anticipate Selecta Biosciences' share price to reach $28.33 in the next twelve months. View Analyst Ratings for Selecta Biosciences.

Here are some recent quotes from research analysts about Selecta Biosciences stock:

• 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (4/20/2017)
• 2. Needham & Company LLC analysts commented, "Selecta presented initial Phase II multi-dose data for SEL-212 on its 4Q16 earnings call. We believe this early data is very encouraging as a clinically active monthly dose appears to have been reached. Dosing continues with 2 additional cohorts. The next update is expected at a conference in June. We remain buyers of SELB as we believe they have both a promising clinical candidate in SEL-212 and a broadly applicable platform to induce tolerance to anti-drug antibodies." (3/28/2017)

Some companies that are related to Selecta Biosciences include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), TESARO (TSRO), Exelixis (EXEL), Bioverativ (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Clovis Oncology (CLVS), Neurocrine Biosciences (NBIX), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Ultragenyx Pharmaceutical (RARE) and GW Pharmaceuticals PLC (GWPH).

Selecta Biosciences' management team includes the folowing people:

• Werner Cautreels Ph.D., Chairman of the Board, President, Chief Executive Officer
• Omid Farokhzad M.D., Co-Founder, Director
• David Siewers, Chief Financial Officer, Treasurer
• Lloyd Johnston Ph.D., Chief Operating Officer, Senior Vice President - Research & development
• Takashi Kei Kishimoto Ph.D., Chief Scientific Officer
• David Abraham J.D., Chief Compliance Officer, General Counsel, Corporate Secretary
• Peter Keller, Chief Business Officer
• Earl Sands M.D., Chief Medical Officer
• Timothy C. Barabe, Independent Director
• Peter Barton Hutt, Independent Director

(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Selecta Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Polaris Venture Management Co. V L.L.C. (0.00%), Flagship Pioneering Inc. (0.00%), FMR LLC (0.00%), JPMorgan Chase & Co. (0.00%), Sphera Funds Management LTD. (0.00%) and Perceptive Advisors LLC (0.00%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, Edwin M Kania, Jr, Lloyd P Johnston, Nanodimension Management Ltd, Peter Keller, Takashi Kei Kishimoto and Timothy A Springer. View Institutional Ownership Trends for Selecta Biosciences.

Selecta Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., JPMorgan Chase & Co. and Morgan Stanley. Company insiders that have sold Selecta Biosciences stock in the last year include David Abraham, Edwin M Kania, Jr, Lloyd P Johnston, Peter Keller and Takashi Kei Kishimoto. View Insider Buying and Selling for Selecta Biosciences.

Selecta Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Candriam Luxembourg S.C.A., Hikari Power Ltd, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Nanodimension Management Ltd and Timothy A Springer. View Insider Buying and Selling for Selecta Biosciences.

Shares of Selecta Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Selecta Biosciences stock can currently be purchased for approximately $19.87.